Growth Metrics

Halozyme Therapeutics (HALO) Asset Writedowns and Impairment (2019 - 2020)

Historic Asset Writedowns and Impairment for Halozyme Therapeutics (HALO) over the last 2 years, with Q4 2020 value amounting to $52000.0.